Trinity Biotech (TRIB) Current Deferred Revenue (2016 - 2020)

Trinity Biotech has disclosed Current Deferred Revenue across 5 years of filings, most recently posting $4.4 million for Q4 2020.

• Current Deferred Revenue for Q4 2020 came in at $4.4 million, up 1422.26% year-over-year; the trailing twelve-month figure through Dec 2020 was $4.4 million (up 1422.26% YoY), and the FY2020 annual result was $4.4 million, up 1422.26% from the prior year.
• Current Deferred Revenue came in at $4.4 million for Q4 2020 at Trinity Biotech, up from $292000.0 in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $4.4 million in Q4 2020 to a low of $224000.0 in Q4 2016.
• The 5-year median for Current Deferred Revenue is $292000.0 (2019), against an average of $1.1 million.
• Across the five-year window, Current Deferred Revenue decreased 6.41% in 2019 and jumped 1422.26% in 2020, its largest moves.
• Trinity Biotech's Current Deferred Revenue stood at $224000.0 in 2016, then grew by 24.11% to $278000.0 in 2017, then gained by 12.23% to $312000.0 in 2018, then fell by 6.41% to $292000.0 in 2019, then surged by 1422.26% to $4.4 million in 2020.
• The last three Current Deferred Revenue figures came in at $4.4 million (Q4 2020), $292000.0 (Q4 2019), and $312000.0 (Q4 2018), per Business Quant data.